Base de dados : MEDLINE
Pesquisa : D02.691.750.740.760 [Categoria DeCS]
Referências encontradas : 291 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 30 ir para página                         

  1 / 291 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27062344
[Au] Autor:Cabral L; Yu RQ; Crane S; Giovanella P; Barkay T; Camargo FA
[Ad] Endereço:Microbial Resources Division - Research Center for Chemistry, Biology and Agriculture (CPQBA), University of Campinas (UNICAMP), Av. Alexandre Cazelatto, 999, Campinas, SP 13148-218, Brazil. Electronic address: luc.g.cabral@gmail.com.
[Ti] Título:Methylmercury degradation by Pseudomonas putida V1.
[So] Source:Ecotoxicol Environ Saf;130:37-42, 2016 Aug.
[Is] ISSN:1090-2414
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Environmental contamination of mercury (Hg) has caused public health concerns with focuses on the neurotoxic substance methylmercury, due to its bioaccumulation and biomagnification in food chains. The goals of the present study were to examine: (i) the transformation of methylmercury, thimerosal, phenylmercuric acetate and mercuric chloride by cultures of Pseudomonas putida V1, (ii) the presence of the genes merA and merB in P. putida V1, and (iii) the degradation pathways of methylmercury by P. putida V1. Strain V1 cultures readily degraded methylmercury, thimerosal, phenylmercury acetate, and reduced mercuric chloride into gaseous Hg(0). However, the Hg transformation in LB broth by P. putida V1 was influenced by the type of Hg compounds. The merA gene was detected in P. putida V1, on the other hand, the merB gene was not detected. The sequencing of this gene, showed high similarity (100%) to the mercuric reductase gene of other Pseudomonas spp. Furthermore, tests using radioactive (14)C-methylmercury indicated an uncommon release of (14)CO2 concomitant with the production of Hg(0). The results of the present work suggest that P. putida V1 has the potential to remove methylmercury from contaminated sites. More studies are warranted to determine the mechanism of removal of methylmercury by P. putida V1.
[Mh] Termos MeSH primário: Compostos de Metilmercúrio/metabolismo
Pseudomonas putida/metabolismo
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Poluentes Ambientais/metabolismo
Recuperação e Remediação Ambiental
Liases/genética
Cloreto de Mercúrio/metabolismo
Oxirredutases/genética
Acetato de Fenilmercúrio/metabolismo
Pseudomonas putida/genética
Timerosal/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Environmental Pollutants); 0 (Methylmercury Compounds); 2225PI3MOV (Thimerosal); 53GH7MZT1R (Mercuric Chloride); EC 1.- (Oxidoreductases); EC 1.16.- (mercuric reductase); EC 4.- (Lyases); EC 4.99.1.2 (MerB protein, Bacteria); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160411
[St] Status:MEDLINE


  2 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24670518
[Au] Autor:Sudhakar YA; Verma RK; Pawar SC
[Ad] Endereço:1] Cell Signaling Laboratory, Bioscience Division, Center for Cancer and Metabolism, SRI International, Menlo Park, CA 94025, USA [2] Cell Signaling and Tumor Angiogenesis Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE 68131, USA.
[Ti] Título:Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.
[So] Source:Sci Rep;4:4136, 2014 Mar 26.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:α1(IV)NC1 inhibits angiogenesis by regulating MAPK activation, this biological function was partly attributed α1(IV)NC1 binding to α1ß1-integrin. However, its potent antiangiogenic activity and the molecular targets of α1(IV)NC1 has not been investigated. In the present study, the regulation of MMP-2 activation by α1(IV)NC1 was evaluated. α1ß1-integrin which is required for inhibition of angiogenesis is not playing a role in cellular invasion and inhibition of MMP-2 activation by α1(IV)NC1. We found that α1(IV)NC1 binds the CBD of MMP-2 and forming a stable complex that prevents activation of MMP-2. The antiangiogenic activity of α1(IV)NC1 is mediated, in part, by this binding activity. In addition, up-regulation of TIMP-2 by α1(IV)NC1 led to saturation of MT1-MMP binding sites, which in turn led to inhibition of MMP-2 activation. In-vivo studies using α1-integrin null-mice treated with higher doses of α1(IV)NC1 showed integrin independent inhibition of tumor growth and active-MMP-2, without affecting MMP-9, MMP-7 and angiostatin.
[Mh] Termos MeSH primário: Colágeno Tipo IV/metabolismo
Metaloproteinase 2 da Matriz/metabolismo
Domínios e Motivos de Interação entre Proteínas
[Mh] Termos MeSH secundário: Angiostatinas/metabolismo
Animais
Colágeno Tipo IV/química
Colágeno Tipo IV/genética
Ativação Enzimática/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana/metabolismo
Seres Humanos
Integrina alfa1/genética
Metaloproteinase 14 da Matriz/metabolismo
Metaloproteinase 7 da Matriz/metabolismo
Metaloproteinase 9 da Matriz/metabolismo
Camundongos
Camundongos Knockout
Neoplasias/tratamento farmacológico
Neoplasias/genética
Neoplasias/metabolismo
Neoplasias/patologia
Neovascularização Patológica/tratamento farmacológico
Neovascularização Patológica/metabolismo
Neovascularização Fisiológica/efeitos dos fármacos
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/farmacologia
Domínios e Motivos de Interação entre Proteínas/genética
Proteínas Recombinantes/genética
Proteínas Recombinantes/isolamento & purificação
Proteínas Recombinantes/farmacologia
Fator A de Crescimento do Endotélio Vascular/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Collagen Type IV); 0 (Integrin alpha1); 0 (Recombinant Proteins); 0 (Vascular Endothelial Growth Factor A); 6283-24-5 (4-aminophenylmercuriacetate); 86090-08-6 (Angiostatins); EC 3.4.24.23 (Matrix Metalloproteinase 7); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 3.4.24.80 (Matrix Metalloproteinase 14); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140328
[St] Status:MEDLINE
[do] DOI:10.1038/srep04136


  3 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24355101
[Au] Autor:Marshall AC; Shaltout HA; Pirro NT; Rose JC; Diz DI; Chappell MC
[Ad] Endereço:Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston Salem, NC, United States.
[Ti] Título:Enhanced activity of an angiotensin-(1-7) neuropeptidase in glucocorticoid-induced fetal programming.
[So] Source:Peptides;52:74-81, 2014 Feb.
[Is] ISSN:1873-5169
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We previously identified angiotensin converting enzyme (ACE) and an endopeptidase activity that degraded angiotensin-(1-7) [Ang-(1-7)] to Ang-(1-5) and Ang-(1-4), respectively, in the cerebrospinal fluid (CSF) of 6-month old male sheep. The present study undertook a more comprehensive analysis of the CSF peptidase that converts Ang-(1-7) to Ang-(1-4) in control and in utero betamethasone-exposed sheep (BMX). Characterization of the Ang-(1-7) peptidase revealed that the thiol agents 4-aminophenylmercuric acetate (APMA) and p-chloromercuribenzoic acid (PCMB), as well as the metallo-chelators o-phenanthroline and EDTA essentially abolished the enzyme activity. Additional inhibitors for serine, aspartyl, and cysteine proteases, as well as selective inhibitors against the endopeptidases neprilysin, neurolysin, prolyl and thimet oligopeptidases did not attenuate enzymatic activity. Competition studies against the peptidase revealed similar IC50s for Ang-(1-7) (5µM) and Ang II (3µM), but lower values for Ala(1)-Ang-(1-7) and Ang-(2-7) of 1.8 and 2.0µM, respectively. In contrast, bradykinin exhibited a 6-fold higher IC50 (32µM) than Ang-(1-7) while neurotensin was a poor competitor. Mean arterial pressure (78±1 vs. 94±2mmHg, N=4-5, P<0.01) and Ang-(1-7) peptidase activity (14.2±1 vs 32±1.5fmol/min/ml CSF, N=5, P<0.01) were higher in the BMX group, and enzyme activity inversely correlated with Ang-(1-7) content in CSF. Lower Ang-(1-7) expression in brain is linked to baroreflex impairment in hypertension and aging, thus, increased activity of an Ang-(1-7) peptidase may contribute to lower CSF Ang-(1-7) levels, elevated blood pressure and impaired reflex function in this model of fetal programming.
[Mh] Termos MeSH primário: Envelhecimento/metabolismo
Angiotensina I
Barorreflexo/fisiologia
Hipertensão/metabolismo
Fragmentos de Peptídeos
Peptidil Dipeptidase A
[Mh] Termos MeSH secundário: Angiotensina I/química
Angiotensina I/metabolismo
Animais
Ácido Edético/química
Masculino
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/metabolismo
Peptidil Dipeptidase A/química
Peptidil Dipeptidase A/metabolismo
Fenantrolinas/química
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/química
Ovinos
Especificidade por Substrato/fisiologia
Ácido p-Cloromercurobenzoico/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Peptide Fragments); 0 (Phenanthrolines); 59-85-8 (p-Chloromercuribenzoic Acid); 6283-24-5 (4-aminophenylmercuriacetate); 9041-90-1 (Angiotensin I); 9G34HU7RV0 (Edetic Acid); EC 3.4.15.1 (Peptidyl-Dipeptidase A); IJ3FUK8MOF (angiotensin I (1-7)); OSX88361UX (Phenylmercuric Acetate); W4X6ZO7939 (1,10-phenanthroline)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131221
[St] Status:MEDLINE


  4 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23525277
[Au] Autor:Cao L; Wang H; Wang F
[Ad] Endereço:Department of Ophthalmology, Shanghai Tenth People's Hospital affiliated with Tongji University, School of Medicine, Shanghai, P.R. China.
[Ti] Título:Amyloid-ß-induced matrix metalloproteinase-9 secretion is associated with retinal pigment epithelial barrier disruption.
[So] Source:Int J Mol Med;31(5):1105-12, 2013 May.
[Is] ISSN:1791-244X
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Local and chronic inflammation induced by amyloid-ß (Aß) plays a central role in the development of age-related macular degeneration. The retina is an immune-privileged site due to local tissue barrier. Yet, the manner by which immune cells pass through this barrier and accumulate in the retina remains unclear. Matrix metalloproteinases (MMPs) induce barrier disruption via proteolysis of epithelial tight junction (TJ) proteins. We hypothesized that Aß-induced MMP secretion causes disruption of epithelial barrier integrity. To test this hypothesis, human adult retinal pigment epithelial (haRPE) cells were exposed to Aß, and the expression of MMP-2 and MMP-9 was detected using gelatin zymography. To demonstrate the key role of MMPs in modulating epithelial barrier structure, the MMP agonist 4-aminophenylmercuric acetate (APMA), an MMP inhibitor (GM6001) and siRNA against MMP-9 were employed for comparison. We found that MMP-9, secreted by Aß- or APMA-stimulated cells, mediated low transepithelial electrical resistance (TER) and high transepithelial permeability by disrupting TJ proteins. However, these alterations were reduced by the MMP inhibitor GM6001 or by silencing of the MMP-9 gene. Our findings suggest that the degradation of TJ proteins such as zonula occludens-1, occludin and F-actin by MMP-9 secreted by Aß-stimulated cells constitutes an important mechanism in the breakdown of the barrier which contributes to chronic inflammation in the retina of age-related macular degeneration.
[Mh] Termos MeSH primário: Peptídeos beta-Amiloides/farmacologia
Metaloproteinase 9 da Matriz/secreção
Epitélio Pigmentado da Retina/patologia
Epitélio Pigmentado da Retina/secreção
[Mh] Termos MeSH secundário: Adulto
Peptídeos beta-Amiloides/química
Morte Celular/efeitos dos fármacos
Forma Celular/efeitos dos fármacos
Dipeptídeos/farmacologia
Células Epiteliais/efeitos dos fármacos
Células Epiteliais/enzimologia
Seres Humanos
Inflamação/patologia
Mediadores da Inflamação/metabolismo
Interleucina-6/metabolismo
Interleucina-8/metabolismo
Metaloproteinase 2 da Matriz/metabolismo
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/farmacologia
Estrutura Quaternária de Proteína
RNA Interferente Pequeno/metabolismo
Epitélio Pigmentado da Retina/efeitos dos fármacos
Proteínas de Junções Íntimas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Dipeptides); 0 (IL6 protein, human); 0 (IL8 protein, human); 0 (Inflammation Mediators); 0 (Interleukin-6); 0 (Interleukin-8); 0 (N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide); 0 (RNA, Small Interfering); 0 (Tight Junction Proteins); 6283-24-5 (4-aminophenylmercuriacetate); EC 3.4.24.24 (MMP2 protein, human); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.35 (MMP9 protein, human); EC 3.4.24.35 (Matrix Metalloproteinase 9); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1310
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130326
[St] Status:MEDLINE
[do] DOI:10.3892/ijmm.2013.1310


  5 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23103634
[Au] Autor:Tezvergil-Mutluay A; Mutluay M; Seseogullari-Dirihan R; Agee KA; Key WO; Scheffel DL; Breschi L; Mazzoni A; Tjäderhane L; Nishitani Y; Tay FR; Pashley DH
[Ad] Endereço:Adhesive Dentistry Research Group, Institute of Dentistry, University of Turku, Turku, Finland.
[Ti] Título:Effect of phosphoric acid on the degradation of human dentin matrix.
[So] Source:J Dent Res;92(1):87-91, 2013 Jan.
[Is] ISSN:1544-0591
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study determined if dentin proteases are denatured by phosphoric acid (PA) used in etch-and-rinse dentin adhesives. Dentin beams were completely demineralized with EDTA for 30 days. We "acid-etched" experimental groups by exposing the demineralized dentin beams to 1, 10, or 37 mass% PA for 15 sec or 15 min. Control beams were not exposed to PA but were incubated in simulated body fluid for 3 days to assay their total endogenous telopeptidase activity, by their ability to solubilize C-terminal crosslinked telopeptides ICTP and CTX from insoluble dentin collagen. Control beams released 6.1 ± 0.8 ng ICTP and 0.6 ± 0.1 ng CTX/mg dry-wt/3 days. Positive control beams pre-incubated in p-aminophenylmercuric acetate, a compound known to activate proMMPs, released about the same amount of ICTP peptides, but released significantly less CTX. Beams immersed in 1, 10, or 37 mass% PA for 15 sec or 15 min released amounts of ICTP and CTX similar to that released by the controls (p > 0.05). Beams incubated in galardin, an MMP inhibitor, or E-64, a cathepsin inhibitor, blocked most of the release of ICTP and CTX, respectively. It is concluded that PA does not denature endogenous MMP and cathepsin activities of dentin matrices.
[Mh] Termos MeSH primário: Dentina/efeitos dos fármacos
Ácidos Fosfóricos/farmacologia
[Mh] Termos MeSH secundário: Catepsinas/antagonistas & inibidores
Colágeno Tipo I/análise
Colagenases/efeitos dos fármacos
Inibidores de Cisteína Proteinase/farmacologia
Dentina/enzimologia
Dipeptídeos/farmacologia
Ativadores de Enzimas/farmacologia
Precursores Enzimáticos/efeitos dos fármacos
Seres Humanos
Leucina/análogos & derivados
Leucina/farmacologia
Teste de Materiais
Inibidores de Metaloproteinases de Matriz/farmacologia
Metaloproteinases da Matriz/efeitos dos fármacos
Peptídeo Hidrolases/efeitos dos fármacos
Peptídeos/análise
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/farmacologia
Desnaturação Proteica
Reagentes de Sulfidrila/farmacologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Collagen Type I); 0 (Cysteine Proteinase Inhibitors); 0 (Dipeptides); 0 (Enzyme Activators); 0 (Enzyme Precursors); 0 (Matrix Metalloproteinase Inhibitors); 0 (N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide); 0 (Peptides); 0 (Phosphoric Acids); 0 (Sulfhydryl Reagents); 0 (collagen type I trimeric cross-linked peptide); 6283-24-5 (4-aminophenylmercuriacetate); E4GA8884NN (phosphoric acid); EC 3.4.- (Cathepsins); EC 3.4.- (Peptide Hydrolases); EC 3.4.24.- (Collagenases); EC 3.4.24.- (Matrix Metalloproteinases); GMW67QNF9C (Leucine); OSX88361UX (Phenylmercuric Acetate); R76F7856MV (E 64)
[Em] Mês de entrada:1302
[Cu] Atualização por classe:161025
[Lr] Data última revisão:
161025
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:121030
[St] Status:MEDLINE
[do] DOI:10.1177/0022034512466264


  6 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22514262
[Au] Autor:Xu Y; Zhao D; Gao C; Zhou L; Pang G; Sun S
[Ad] Endereço:Henan Eye Institute, Department of Ophthalmology, Henan Provincial People's Hospital, Zhengzhou, China. xuyan990301@yahoo.com.cn
[Ti] Título:In vitro activity of phenylmercuric acetate against ocular pathogenic fungi.
[So] Source:J Antimicrob Chemother;67(8):1941-4, 2012 Aug.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the antifungal activity of phenylmercuric acetate against ocular pathogenic fungi in vitro and develop new antifungal eye drops to combat keratomycosis. METHODS: The in vitro activity of phenylmercuric acetate was assessed against 261 isolates of ocular pathogenic fungi that included 136 Fusarium spp. isolates, 98 Aspergillus spp. isolates, 10 Alternaria alternata isolates and 17 other pathogens. The activity of phenylmercuric acetate was compared with the activities of amphotericin B and natamycin. In vitro susceptibility testing was performed by broth microdilution assay, in accordance with the CLSI (formerly NCCLS) M38-A guidelines for filamentous fungi. RESULTS: MIC90s of phenylmercuric acetate were 0.0156, 0.0156, 0.0156 and 0.0156 mg/L for Fusarium spp., Aspergillus spp., A. alternata and other pathogens, respectively. MIC90s of amphotericin B were 2, 2, 1 and 1 mg/L for Fusarium spp., Aspergillus spp., A. alternata and other pathogens, respectively. MIC90s of natamycin were 8, 32, 4 and 4 mg/L for Fusarium spp., Aspergillus spp., A. alternata and other pathogens, respectively. CONCLUSIONS: Phenylmercuric acetate has promising antifungal activity, which is significantly superior to the activities of amphotericin B and natamycin against a wide variety of ocular pathogenic fungi based on comparative MIC values. Additional evaluation is required to determine its clinical utility.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Infecções Oculares Fúngicas/microbiologia
Fungos/efeitos dos fármacos
Fungos/isolamento & purificação
Acetato de Fenilmercúrio/farmacologia
[Mh] Termos MeSH secundário: Anfotericina B/farmacologia
Seres Humanos
Testes de Sensibilidade Microbiana
Natamicina/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antifungal Agents); 7XU7A7DROE (Amphotericin B); 8O0C852CPO (Natamycin); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120420
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dks133


  7 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21879607
[Au] Autor:Löwy I
[Ad] Endereço:CERMES (INSERM, CNRS, EHESS), 7 rue Guy Moquet, 94801 Vuillejuif cedex, France. lowy@vjf.cnrs.fr
[Ti] Título:'Sexual chemistry' before the pill: science, industry and chemical contraceptives, 1920-1960.
[So] Source:Br J Hist Sci;44(161 Pt 2):245-74, 2011 Jun.
[Is] ISSN:0007-0874
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The history of contraceptives met the history of drugs long before the invention of the contraceptive pill. In the first half of the twentieth century, numerous pharmaceutical laboratories, including major ones, manufactured and marketed chemical contraceptives: jellies, suppositories, creams, powders and foams applied locally to prevent conception. Efforts to put an end to the marginal status of these products and to transform them into 'ethical' drugs played an important role in the development of standardized laboratory tests of efficacy of contraceptive preparations; debates on the validity of such tests; evaluation of the long-term toxicity of chemical compounds; and the rise of collaborations between activists, non-profit organizations and the pharmaceutical industry. Chemical contraceptives were initially associated with quack medicine, shady commercial practices and doubtful morality. Striving to change the status of contraceptives and to promote safe and efficient products that reduced fertility in humans shaped some of the key features of the present-day production and regulation of pharmaceuticals.
[Mh] Termos MeSH primário: Espermicidas/história
[Mh] Termos MeSH secundário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/história
História do Século XX
Seres Humanos
Acetato de Fenilmercúrio/história
Reino Unido
Estados Unidos
Cremes, Espumas e Géis Vaginais/história
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Spermatocidal Agents); 0 (Vaginal Creams, Foams, and Jellies); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1110
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:QIS
[Da] Data de entrada para processamento:110902
[St] Status:MEDLINE


  8 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21743026
[Au] Autor:Wright C; Pilkington R; Callaghan M; McClean S
[Ad] Endereço:Centre of Microbial Host Interactions, Institute of Technology Tallaght, Dublin, Ireland.
[Ti] Título:Activation of MMP-9 by human lung epithelial cells in response to the cystic fibrosis-associated pathogen Burkholderia cenocepacia reduced wound healing in vitro.
[So] Source:Am J Physiol Lung Cell Mol Physiol;301(4):L575-86, 2011 Oct.
[Is] ISSN:1522-1504
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Burkholderia cepacia complex is a group of bacterial pathogens that cause opportunistic infections in cystic fibrosis (CF). The most virulent of these is Burkholderia cenocepacia. Matrix metalloproteinases (MMPs) are upregulated in CF patients. The aim of this work was to examine the role of MMPs in the pathogenesis of B. cepacia complex, which has not been explored to date. Real-time PCR analysis showed that B. cenocepacia infection upregulated MMP-2 and MMP-9 genes in the CF lung cell line CFBE41o- within 1 h, whereas MMP-2, -7, and -9 genes were upregulated in the non-CF lung cell line 16HBE14o-. Conditioned media from both cell lines showed increased MMP-9 activation following B. cenocepacia infection. Conditioned media from B. cenocepacia-infected cells significantly reduced the rate of wound healing in confluent lung epithelia (P < 0.05), in contrast to conditioned media from Pseudomonas aeruginosa-infected cells, which showed predominant MMP-2 activation. Treatment of control conditioned media from both cell lines with the MMP activator 4-aminophenylmercuric acetate (APMA) also resulted in clear activation of MMP-9 and to a much lesser extent MMP-2. APMA treatment of control media also delayed the repair of wound healing in confluent epithelial cells. Furthermore, specific inhibition of MMP-9 in medium from cells exposed to B. cenocepacia completely reversed the delay in wound repair. These data suggest that MMP-9 plays a role in the reduced epithelial repair observed in response to B. cenocepacia infection and that its activation following B. cenocepacia infection contributes to the pathogenesis of this virulent pathogen.
[Mh] Termos MeSH primário: Infecções por Burkholderia/enzimologia
Meios de Cultivo Condicionados/farmacologia
Fibrose Cística/enzimologia
Células Epiteliais/efeitos dos fármacos
Pulmão/enzimologia
Metaloproteinase 9 da Matriz/metabolismo
Cicatrização/efeitos dos fármacos
[Mh] Termos MeSH secundário: Infecções por Burkholderia/complicações
Infecções por Burkholderia/microbiologia
Infecções por Burkholderia/patologia
Burkholderia cenocepacia/crescimento & desenvolvimento
Linhagem Celular
Meios de Cultivo Condicionados/química
Fibrose Cística/complicações
Fibrose Cística/microbiologia
Fibrose Cística/patologia
DNA Complementar
Células Epiteliais/citologia
Expressão Gênica
Seres Humanos
Pulmão/microbiologia
Pulmão/patologia
Metaloproteinase 2 da Matriz/genética
Metaloproteinase 2 da Matriz/metabolismo
Metaloproteinase 2 da Matriz/secreção
Metaloproteinase 7 da Matriz/genética
Metaloproteinase 7 da Matriz/metabolismo
Metaloproteinase 7 da Matriz/secreção
Metaloproteinase 9 da Matriz/genética
Metaloproteinase 9 da Matriz/secreção
Inibidores de Metaloproteinases de Matriz
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/farmacologia
Reação em Cadeia da Polimerase
Inibidores de Proteases/farmacologia
Infecções por Pseudomonas/enzimologia
Infecções por Pseudomonas/microbiologia
Infecções por Pseudomonas/patologia
Pseudomonas aeruginosa/crescimento & desenvolvimento
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Culture Media, Conditioned); 0 (DNA, Complementary); 0 (Matrix Metalloproteinase Inhibitors); 0 (Protease Inhibitors); 6283-24-5 (4-aminophenylmercuriacetate); EC 3.4.24.23 (MMP7 protein, human); EC 3.4.24.23 (Matrix Metalloproteinase 7); EC 3.4.24.24 (MMP2 protein, human); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.35 (Matrix Metalloproteinase 9); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1112
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110712
[St] Status:MEDLINE
[do] DOI:10.1152/ajplung.00226.2010


  9 / 291 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21699515
[Au] Autor:Landeck L; Schalock P; Baden L; González E
[Ad] Endereço:Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
[Ti] Título:Contact sensitization pattern in 172 atopic subjects.
[So] Source:Int J Dermatol;50(7):806-10, 2011 Jul.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Some authors have claimed a decreased cell-mediated immunity among atopic individuals, which would lead to observations of decreased rates of allergic contact dermatitis (ACD). OBJECTIVES: The purpose of our study was to investigate contact sensitization patterns in atopic subjects compared with non-atopic subjects. METHODS: Patch test data for 1247 patients undergoing patch testing at Massachusetts General Hospital between 1990 and 2006 were reviewed. Using accepted criteria, 172 subjects were classified as atopic individuals (AIs), and 1075 were classified as non-atopic individuals (NAIs). Sensitization rates were compared between these two groups. RESULTS: Sensitization rates (65.0% and 57.4% in the AI and NAI groups, respectively) and average numbers of positive responses (1.5 and 1.2 in the AI and NAI groups, respectively) were higher in AIs. Leading allergens observed were similar for both groups. Sensitization to potassium dichromate and phenylmercuric acetate was significantly greater in the AI group. The most frequent diagnosis in both groups was ACD (41.9% and 45.5% in the AI and NAI groups, respectively). In addition, more NAIs who were employed in occupations with exposure to wet and/or irritant conditions had hand eczema (P < 0.005). CONCLUSIONS: Atopic individuals were shown to be at least as likely to have ACD as NAIs. The most common sensitizers were similar in both groups, suggesting common sources of sensitization.
[Mh] Termos MeSH primário: Dermatite Alérgica de Contato/diagnóstico
Dermatite Alérgica de Contato/epidemiologia
Dermatite Atópica/diagnóstico
Dermatite Atópica/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Alérgenos/imunologia
Bases de Dados Factuais/estatística & dados numéricos
Dermatite Alérgica de Contato/imunologia
Dermatite Atópica/imunologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Doenças Profissionais/diagnóstico
Doenças Profissionais/epidemiologia
Doenças Profissionais/imunologia
Ocupações/estatística & dados numéricos
Testes do Emplastro
Acetato de Fenilmercúrio/imunologia
Dicromato de Potássio/imunologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Allergens); OSX88361UX (Phenylmercuric Acetate); T4423S18FM (Potassium Dichromate)
[Em] Mês de entrada:1110
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110625
[St] Status:MEDLINE
[do] DOI:10.1111/j.1365-4632.2010.04754.x


  10 / 291 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21055468
[Au] Autor:Durigova M; Nagase H; Mort JS; Roughley PJ
[Ad] Endereço:Genetics Unit, Shriners Hospital for Children, Montreal, Canada.
[Ti] Título:MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein.
[So] Source:Matrix Biol;30(2):145-53, 2011 Mar.
[Is] ISSN:1569-1802
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Aggrecan degradation in articular cartilage occurs predominantly through proteolysis and has been attributed to the action of members of the matrix metalloproteinase (MMP) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) families. Both families of enzymes cleave aggrecan at specific sites within the aggrecan core protein. One cleavage site within the interglobular domain (IGD), between Glu(373-374)Ala and five additional sites in the chondroitin sulfate-2 (CS-2) region of aggrecan were characterized as "aggrecanase" (ADAMTS) cleavage sites, while cleavage between Ser(341-342)Phe within the IGD of bovine aggrecan is attributed to MMP action. The objective of this study was to assess the cleavage efficiency of MMPs relative to ADAMTS and their contribution to aggrecan proteolysis in vitro. The analysis of aggrecan IGD degradation in bovine articular cartilage explants treated with catabolic cytokines over a 19-day period showed that MMP-mediated degradation of aggrecan within the IGD can only be observed following day 12 of culture. This delay is associated with the lack of activation of proMMPs during the first 12 days of culture. Analysis of MMP1, 2, 3, 7, 8, 9, 12, 13 and ADAMTS5 efficiencies at cleaving within the aggrecan IGD and CS-2 region in vitro was carried out by the digestion of bovine aggrecan with the various enzymes and Western blot analysis using aggrecan anti-G1 and anti-G3 antibodies. Of these MMPs, MMP12 was the most efficient at cleaving within the aggrecan IGD. In addition to cleavage in the IGD, MMP, 3, 7, 8 and 12 were also able to degrade the aggrecan CS-2 region. MMP3 and MMP12 were able to degrade aggrecan at the very C-terminus of the CS-2 region, cleaving the Glu(2047-2048)Ala bond which was previously shown to be cleaved by ADAMTS5. However, in comparison to ADAMTS5, MMP3 was about 100 times and 10 times less efficient at cleaving within the aggrecan IGD and CS-2 regions, respectively. Collectively, our results showed that the delayed activation of proMMPs and the relatively low cleavage efficiency of MMPs can explain the minor contribution of these enzymes to aggrecan catabolism in vivo. This study also uncovered a potential role for MMPs in the C-terminal truncation of aggrecan.
[Mh] Termos MeSH primário: Proteínas ADAM/metabolismo
Agrecanas/metabolismo
Cartilagem/metabolismo
Endopeptidases/metabolismo
Metaloproteinases da Matriz Secretadas/metabolismo
[Mh] Termos MeSH secundário: Proteínas ADAM/genética
Agrecanas/genética
Animais
Cartilagem/efeitos dos fármacos
Cartilagem/enzimologia
Bovinos
Endopeptidases/genética
Precursores Enzimáticos/metabolismo
Gelatinases/metabolismo
Interleucina-1beta/farmacologia
Isoenzimas/genética
Isoenzimas/metabolismo
Metaloproteinase 1 da Matriz/genética
Metaloproteinase 1 da Matriz/metabolismo
Metaloproteinase 12 da Matriz/genética
Metaloproteinase 12 da Matriz/metabolismo
Metaloproteinase 2 da Matriz/metabolismo
Metaloproteinase 3 da Matriz/genética
Metaloproteinase 3 da Matriz/metabolismo
Metaloproteinase 7 da Matriz/genética
Metaloproteinase 7 da Matriz/metabolismo
Metaloproteinase 8 da Matriz/genética
Metaloproteinase 8 da Matriz/metabolismo
Metaloproteinase 9 da Matriz/metabolismo
Metaloproteinases da Matriz Secretadas/genética
Oncostatina M/farmacologia
Fragmentos de Peptídeos/metabolismo
Acetato de Fenilmercúrio/análogos & derivados
Acetato de Fenilmercúrio/farmacologia
Proteínas Recombinantes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aggrecans); 0 (Enzyme Precursors); 0 (Interleukin-1beta); 0 (Isoenzymes); 0 (Peptide Fragments); 0 (Recombinant Proteins); 106956-32-5 (Oncostatin M); 6283-24-5 (4-aminophenylmercuriacetate); EC 3.4.- (Endopeptidases); EC 3.4.24.- (ADAM Proteins); EC 3.4.24.- (Gelatinases); EC 3.4.24.- (Matrix Metalloproteinases, Secreted); EC 3.4.24.- (pro-matrix metalloproteinase 9); EC 3.4.24.- (progelatinase); EC 3.4.24.17 (Matrix Metalloproteinase 3); EC 3.4.24.23 (Matrix Metalloproteinase 7); EC 3.4.24.24 (Matrix Metalloproteinase 2); EC 3.4.24.34 (Matrix Metalloproteinase 8); EC 3.4.24.35 (Matrix Metalloproteinase 9); EC 3.4.24.65 (Matrix Metalloproteinase 12); EC 3.4.24.7 (Matrix Metalloproteinase 1); EC 3.4.99.- (aggrecanase); OSX88361UX (Phenylmercuric Acetate)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:161122
[Lr] Data última revisão:
161122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101109
[St] Status:MEDLINE
[do] DOI:10.1016/j.matbio.2010.10.007



página 1 de 30 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde